

## Drug and Therapeutics Committee – Minutes – Confirmed

<b>Date / Time</b>	Thursday 12 <sup>th</sup> November 2020 8:15am – 9:30am
<b>Venue</b>	Webex
<b>Chair</b>	Prof M Lind, Vice Chair, Professor of Oncology
<b>Notes / Action Points</b>	Mrs W Hornsby, Senior Pharmacy Technician
<b>Quorate: Yes / No</b>	Yes
<b>Attendance</b>	<p>Mr P O'Brien, Deputy Chief Pharmacist</p> <p>Dr S Raise, GP ER CCG</p> <p>Mr K McCorry, Medicines Optimisation Pharmacist, NECS</p> <p>Dr B Ali, GP Hull CCG</p> <p>Ms J Morgan, Professional Secretary, Principal Pharmacist – Formulary</p> <p>Dr A Samson, Consultant Infectious Diseases (until 9am)</p> <p>Mr D Corral, Chief Pharmacist, Clinical Director Therapy &amp; Therapeutics</p> <p>Dr O Ogunbambi, Consultant Rheumatologist</p> <p>Mr A Dawood, Consultant Anaesthetist</p> <p>Dr H Klonin, Consultant Paediatrician</p> <p>Dr E Balakumar, Consultant Anaesthetist</p>
<b>Apologies</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Guests</b>	<p>Ms S Westerhold, Principal Pharmacist Surgery</p> <p>Mr D Mcauley, Digital Nurse EPMA</p> <p>Mr F McLachlan Senior Pharmacy Technician EPMA/Antibiotics</p> <p>Mrs H Hart Senior Pharmacy Technician EPMA</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p><b>Oxycodone Use in Acute Surgical Patients &amp; The Role of EPMA</b></p> <p>SW discussed the general culture within the trust around prescribing oxycodone first line post-surgery. HUTH have the highest DDDs in the country for comparable trusts. This also affects community prescribing with Hull and East Riding CCGs also having high proportion of oxycodone prescribing. The pain team are preparing a new guideline looking at moving to morphine as first line analgesia post-surgery and new information for patients' pre-op and post op. One of the main issues highlighted was lack of review on wards this should be performed 3 days after initiation.</p> <p>EPMA could help with this new guideline through order sets for surgery type, by adding pop ups three days' post prescribing to request review, or adding pre-set durations; however, none of the ePMA solutions are perfect. Indication could also be added to IDL to make GPs aware patient should be stepped down and information about appropriate step down regimens.</p> <p>The committee were in favour of the proposal, KMc said it was a much welcomed change</p> <p><b>Remdesivir Guideline – Update</b></p> <p>AS informed the committee that the Remdesivir guideline has been updated. Nationally more stock is now available according to oxygen usage of trust. This will be assessed by 4C tool which looks at age, comorbidities, kidney and liver function by admitting medical team. AS said the updates were sensible and will aid roll out as ID will not be able to assess every single patient who may potentially benefit due to sheer patient numbers. The new guideline complies with NHSE commissioning policy</p>					
2020.11.01	<b>Apologies</b>	As above					11.20
2020.11.02	<b>Declarations of Interest</b>	None this month					11.20

2020.11.03	<b>Minutes of the previous meeting</b>	<b>Approved</b> Amend spelling mistake on page 2	WH to amend		WH	12/20	
2020.11.04	<b>Action Tracker</b>	<p><b>New Product Requests</b> POB has discussed Dupilumab with Mr Vize, due to the product being available via EAMS the finance is quite complicated and Mr Vize felt there should be a robust failsafe. POB had explained the follow up email and further discussion to clarify the fail safe mechanism</p> <p><b>Minutes</b> WH has updated minutes to include change to glycopyrronium liquid.</p> <p><b>New Product Requests</b> AM has written to applicants and WH has updated formulary</p> <p><b>NICE Guidance</b> JM has chased ARIA forms for TA643 and TA644 Entrectinib and has been informed these are being written. ML agreed to chase</p> <p><b>NICE Guidance</b> JM has chased TA649 Polatuzamab vedotin with rituximab and bendamustine and ML agreed to chase.</p> <p><b>NICE Guidance</b> TA651 Naldemedine for treatment of opioid induced constipation JM has emailed palliative care consultants but the majority were on leave, JM agreed to chase.</p> <p><b>MHRA DSU</b> KMc has circulated to hot topics the use of fentanyl in opioid naïve patients</p> <p><b>Trust Guidelines</b> AM has written to ACAT and informed them D&amp;T approved the update to Empiric Antibiotic Therapy in Adults</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>JM/ML to chase again</p> <p>JM/ML to chase again</p> <p>JM to chase again</p> <p>Action complete</p> <p>Action complete</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Chase again</p> <p>Chase again</p> <p>Chase again</p> <p>No further action</p> <p>No further action</p>	<p>POB</p> <p>WH</p> <p>AM/WH</p> <p>JM/ML</p> <p>JM/ML</p> <p>JM</p> <p>KMc</p> <p>AM</p>	<p></p> <p></p> <p></p> <p>11/20</p> <p>11/20</p> <p>11/20</p> <p></p> <p></p>	<p>11/20</p> <p>11/20</p> <p>11/20</p> <p></p> <p></p> <p></p> <p>11/20</p> <p>11/20</p>

		<b>Trust Guidelines</b> JM has discussed with ID pharmacist the possibility of adding to drug chart, a “mock up” has been produced and will be discussed at SMPC if this route is chosen  <b>Issues to Escalate to OQC</b> NPSA Steroid Card alert has already been discussed at OQC  <b>AOB</b> WH has added “Tinzaparin for use in paediatrics “ to formulary	Action complete	No further action	JM		11/20
			Action complete	No further action	DC		11/20
			Action complete	No further action	WH		11/20
2020.11.05	<b>New Product Requests</b>	<b>ARIA Forms</b> TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia  Encorafenib and Cetuximab – Advanced disease with B-Raf V600E mutation – Dr R Roy  Darolutamide - Castrate resistant high risk non-metastatic prostate cancer with LHRH antagonist injections.  <b>EAMS</b> Avelumab – Monotherapy for the first line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum based induction chemotherapy	Approved	WH to update formulary	WH	12/20	
			Approved				
			Approved				
			Approved				
2020.11.06	<b>NICE Guidance</b>	<b>Nice Guidance</b> <ul style="list-style-type: none"> <li>TA652 Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)</li> <li>TA653 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer</li> <li>TA654 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</li> <li>TA655 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy</li> <li>NG183 Behaviour change: digital and mobile health interventions</li> </ul>	Terminated	No further action			11/20
			Already on formulary but will need ARIA forms	JM to chase ARIA forms	JM	12/20	
			Noted				
			Noted				

		<ul style="list-style-type: none"> <li>NG173 COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital</li> <li>NG170 COVID-19 rapid guideline: cystic fibrosis</li> <li>NG163 COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community</li> </ul> <p>Updated to reinforce need for monitoring when switching patients anticoagulation</p> <ul style="list-style-type: none"> <li>NG100 Rheumatoid arthritis in adults: management</li> </ul>	Noted Noted  Noted				
2020.11.07	<b>MHRA Drug Safety Update</b>	5fu, Capecitabine and Tegafur ;DPD testing recommended to identify patients at increased risk of severe and fatal toxicity. ML said the trust already carries out this testing.	Noted	No further action			11/20
2020.11.08	<b>Terms of Reference</b>	Wrong version circulated, but not many changes. JM will circulate updated version post meeting for committee to approve via email.	JM to circulate updated version		JM	12/20	
2020.11.09	<b>Minutes SMPC</b>	None this month					11/20
2020.11.10	<b>Minutes from HERPC</b>	None this month					11/20
2020.11.11	<b>Regional Medicines Optimisation Committees</b>	<p>Hydroxychloroquine retinopathy monitoring consultation Consultation running until 13/11/2020 – contents noted but not for discussion by D&amp;T</p> <p>Buprenorphine long acting injection guidance consultation running until 13/11/2020 – locally commissioned by PH services contents noted but not for discussion by D&amp;T</p>					
2020.11.12	<b>Clinical Guidelines</b>	<p>Electrolyte guidelines (update) Main change to hyperkalaemia treatment recommendations switched from calcium resonium to sodium zirconium in the treatment of life threatening hyperkalaemia due to its quicker onset of action. This update will need to be disseminated throughout trust.</p> <p>Procedure for use of Primary Thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma receiving systemic anti-cancer treatment (New)</p>	<p>JM to reissue posters throughout trust and will also request change to be highlighted on PATTIE</p> <p>Approved with amendments</p>		JM	12/20	

		<p>Procedure for Use of DOAC (Rivaroxaban or Apixaban) for treatment of Cancer Associated VTE (New) Needs Apixaban adding to page 3 and clarification of referral to GP practices</p> <p>The committee felt that both documents were quite clear</p>					
2020.11.13	<b>Correspondence received</b>	None this month					11/20
2020.11.14	<b>Chairs approvals</b>	None this month					11/20
2020.11.15	<b>Issues to escalate to OQC</b>	None this month					11/20
2020.11.16	<b>Any Other Business</b>	<p>POB mentioned that the trust is working on its capacity to supply oxygen to meet the increase in demand</p> <p>JM said there may be a request to add enoxaparin to formulary to aid in the treatment of thrombolysis as the tenecteplase license specifically recommends the use of enoxaparin.</p> <p>SR said he had a patient referred requiring Nefopam but the committee felt this was an issue for HERPC</p> <p>DC said it was appropriate to mention the up and coming Covid Vaccine and that the trust had agreed to follow national guidance as and when it was published.</p> <p>ML offered his apologies for the December Meeting</p>	<p>Noted</p> <p>JM to add if needed</p>				11/20
	<b>Date and Time of Next Meeting</b>	<p><b>Date:</b> Thursday 10th December 2020 <b>Time:</b> 8.15-9.30am <b>Venue:</b> Webex</p>					